urtica
dioica
agglutinin
uda
small
plant
monomer
lectin
kda
size
nacetylglucosamin
specif
inhibit
virus
nidoviral
vitro
current
studi
first
examin
efficaci
uda
replic
differ
sarscov
strain
vero
cell
uda
inhibit
viru
replic
dosedepend
manner
reduc
viru
yield
urbani
strain
gml
vero
cell
uda
test
efficaci
lethal
sarscovinfect
balbc
mous
model
balbc
mice
infect
two
ld
pfu
viru
h
mice
treat
intraperiton
uda
mgkgday
day
treatment
uda
mgkg
significantli
protect
mice
lethal
infect
mouseadapt
sarscov
p
significantli
reduc
viru
lung
titer
virusinfect
mice
receiv
uda
treatment
also
significantli
protect
weight
loss
p
uda
also
effect
reduc
lung
patholog
score
day
viru
exposur
group
mice
receiv
uda
much
lower
lung
weight
placebotr
mice
thu
data
suggest
uda
treatment
sar
infect
mice
lead
substanti
therapeut
effect
protect
mice
death
weight
loss
furthermor
mode
action
uda
vitro
investig
use
live
sarscov
urbani
strain
viru
retrovir
particl
pseudotyp
sarscov
spike
uda
specif
inhibit
replic
live
sarscov
sarscov
pseudotyp
viru
ad
adsorpt
data
suggest
uda
like
inhibit
sarscov
infect
target
earli
stage
replic
cycl
name
adsorpt
penetr
addit
demonstr
uda
neutral
viru
infect
presum
bind
sarscov
spike
glycoprotein
final
target
molecul
inhibit
viru
replic
partial
character
uda
expos
nacetylglucosamin
uda
ad
cell
prior
adsorpt
uda
inhibit
viru
infect
data
support
conclus
uda
might
bind
nacetylglucosaminelik
residu
present
glycosyl
envelop
glycoprotein
therebi
prevent
viru
attach
cell
dl
barnard
ize
high
mortal
morbid
infect
individu
juli
sar
case
nearli
sarsrel
death
report
around
world
studi
molecular
evolut
sarscov
suggest
viru
emerg
nonhuman
sourc
guan
et
al
civet
cat
coronaviru
shown
sequenc
ident
sarscov
limit
number
delet
mutat
virus
sarscov
shown
delet
nucleotid
rel
civet
cat
viru
possibl
suggest
direct
transmiss
civet
human
guan
et
al
viru
transmiss
human
may
occur
civet
see
front
matter
sever
acut
respiratori
syndrom
coronaviru
sarscov
caus
agent
emerg
human
infecti
diseas
sever
acut
respiratori
syndrom
sar
ksiazek
et
al
peiri
et
al
rota
et
al
sar
origin
southern
china
end
charactercat
probabl
infect
bat
trade
chines
wet
market
lau
et
al
li
et
al
infect
caus
sarscov
pose
seriou
threat
human
popul
repres
challeng
antivir
drug
develop
administr
groneberg
et
al
groneberg
et
al
proven
approv
efficaci
agent
treat
sarscov
infect
ribavirin
combin
corticosteroid
frequent
administ
antivir
agent
sar
outbreak
booth
et
al
ho
et
al
peiri
et
al
tsang
et
al
tsui
et
al
howev
ribavirin
alon
nontox
concentr
found
littl
vitro
activ
sarscov
although
improv
clinic
outcom
report
among
sar
patient
receiv
earli
administr
kaletra
plu
ribavirin
corticosteroid
tsang
seto
present
clear
evid
provid
support
clinic
observ
yet
sever
mous
model
vitro
ribavirin
even
found
enhanc
sarscov
infect
barnard
et
al
b
day
et
al
therefor
develop
new
antisarscov
agent
urgent
need
sarscov
viru
close
relat
emerg
reemerg
caus
diseas
numer
type
agent
test
sarscov
vitro
exampl
antibodi
sarscov
spike
protein
shown
block
entri
sui
et
al
small
peptid
deriv
heptad
repeat
hr
region
sarscov
protein
shown
inhibit
sarscov
infect
interfer
sarscov
fusion
target
cell
bosch
et
al
ho
et
al
addit
main
proteas
sar
essenti
replic
cycl
sarscov
key
target
develop
antisar
drug
barnard
kumaki
yang
et
al
antisens
rna
rna
interfer
rnai
technolog
shown
potenti
treat
sever
diseas
includ
sarscov
infect
leonard
schaffer
interferon
also
consid
first
line
defens
viral
infect
earlier
studi
evalu
compound
approv
therapeut
use
human
vitro
inhibitor
sarscov
inhibit
mous
sarscov
replic
model
hybrid
interferon
interferon
alpha
bd
mismatch
doublestrand
ds
rna
interferon
induc
ampligen
poli
poli
shown
potent
inhibit
viru
titer
lung
infect
mice
barnard
et
al
also
demonstr
interferon
inhibit
sarscov
infect
human
bronchial
epitheli
cell
kumaki
et
al
sting
nettl
lectin
urtica
dioica
agglutinin
uda
small
kda
plant
monomer
lectin
nacetylglucosamin
specif
beintema
peuman
van
damm
et
al
demonstr
inhibit
nidoviral
vitro
select
van
der
meer
et
al
keyaert
et
al
show
uda
potent
select
inhibitor
sarscov
frankfurt
strain
ec
ic
result
si
addit
anoth
lectin
mannos
specif
lectin
hippeastrum
hybrid
agglutinin
hha
like
inhibit
sarscov
attach
cell
act
inhibit
viru
end
infecti
viru
cycl
keyaert
et
al
evalu
prophylact
potenti
antivir
direct
sarscov
infect
new
lethal
anim
model
sar
need
facilit
antivir
research
previous
adapt
character
new
strain
sarscov
strain
highli
lethal
balbc
mice
day
et
al
number
compound
test
efficaci
sarscovinfect
balbc
mice
includ
uda
earlier
report
uda
partial
protect
sarscovinfect
mice
day
et
al
uda
mgkgday
shown
significantli
delay
mean
day
death
compar
averag
onset
death
anim
receiv
physiolog
steril
salin
pss
day
p
howev
udatr
anim
surviv
nevertheless
visual
lung
score
day
day
lectin
treatment
experi
lower
observ
lung
placebotr
mice
addit
weight
reduct
chang
day
day
differ
day
day
weight
also
less
lectintr
anim
psstreat
mice
data
suggest
uda
treatment
mice
amelior
lethal
associ
lung
pathogenesi
mice
infect
mouseadapt
sarscov
furthermor
higher
concentr
uda
test
determin
efficaci
reduc
lethal
amelior
pathogenesi
mice
infect
lethal
dose
mouseadapt
sarscov
data
show
increas
concentr
uda
treatment
mgkgday
increas
efficaci
uda
compar
uda
use
mgkgday
posit
result
obtain
vitro
assay
initi
studi
show
efficaci
uda
treatment
significantli
reduc
mortal
lethal
sarscov
mous
model
uda
evalu
lethal
mous
model
sarscov
see
efficaci
could
improv
optim
dosag
regimen
increas
effect
uda
sarscov
balbc
mous
model
term
surviv
also
investig
mode
action
uda
vitro
vero
cell
obtain
american
type
cultur
collect
atcc
manassa
va
routin
grown
minim
essenti
medium
mem
supplement
heatinactiv
fetal
bovin
serum
fb
thermo
fisher
scientif
co
logan
ut
vitro
antivir
assay
serum
reduc
vero
cell
gentamicin
ad
medium
final
concentr
gml
human
primari
embryon
kidney
cell
express
obtain
atcc
cultur
dulbecco
modifi
eagl
medium
dmem
supplement
heatinactiv
fb
cov
strain
urbani
obtain
center
diseas
control
cdc
atlanta
ga
usa
frankfurt
strain
kindli
provid
jindrich
cinatl
klinikum
der
jw
goeth
universitat
frankfurt
main
germani
strain
suppli
heinz
feldman
nation
microbiolog
laboratori
winnipeg
manitoba
canada
strain
receiv
paul
ks
chan
chines
univers
hong
kong
china
strain
propag
titrat
vero
cell
personnel
enter
facil
wore
power
airpurifi
respir
hepa
airmat
saint
paul
mn
full
bodi
protect
tyvek
suit
adapt
human
clinic
isol
strain
urbani
mice
mice
infect
intranas
urbani
strain
use
dilut
cellcultur
amplifi
viru
three
five
day
infect
lung
remov
homogen
dilut
clarifi
lung
homogen
use
reinfect
subsequ
group
mice
infect
step
continu
time
balbc
mice
lung
viru
plaquepurifi
time
yield
viru
caus
sever
lung
diseas
mortal
infect
mice
viru
verifi
sarscov
elisa
pcr
day
et
al
mous
model
anim
infect
three
ld
viru
die
day
day
mortal
achiev
day
lung
sever
inflam
exhibit
extrem
lung
histopatholog
weight
loss
excess
total
initi
bodi
weight
occasion
surviv
anim
may
lose
weight
seem
regain
weight
day
day
live
least
day
viru
titer
lung
often
exceed
ml
titer
peak
day
viru
lung
titer
persist
least
day
mice
surviv
long
plasmid
encod
spike
glycoprotein
sarscov
human
describ
previous
simmon
et
al
provid
simmon
laboratori
plasmid
lucr
pnlluc
encod
replicationincompet
variant
human
immunodefici
viru
type
molecular
clone
nef
gene
replac
firefli
luciferas
luc
report
env
vpr
gene
inactiv
previous
describ
connor
et
al
nacetylglucosaminespecif
sting
nettl
lectin
u
dioica
agglutinin
uda
purchas
ey
laboratori
inc
san
mateo
ca
stock
solut
uda
prepar
concentr
mgml
distil
water
store
c
uda
subsequ
dilut
mem
vitro
experi
vivo
studi
uda
prepar
pss
solut
stock
solut
interferon
alfacon
ifnalfacon
intermun
inc
brisban
ca
provid
concentr
gml
store
c
ifnalfacon
solubil
mem
vitro
experi
final
concentr
ngml
interferon
induc
poli
ic
lc
obtain
ribopharm
corpor
bethesda
md
nacetyldglucosamin
obtain
sigmaaldrich
group
sigmaaldrich
st
loui
mo
modifi
protocol
barnard
et
al
use
vitro
evalu
antivir
efficaci
inhibitor
sarscov
replic
vero
cell
seed
onto
tissu
cultur
plate
test
compound
viru
ad
equal
volum
nearconflu
cell
monolay
tissu
cultur
plate
next
day
multipl
infect
moi
use
rang
order
produc
complet
viru
cytopath
effect
cpe
cell
viru
control
well
within
day
plate
incub
c
cell
viru
control
well
show
complet
viral
cpe
observ
light
microscopi
concentr
drug
assay
viru
inhibit
viral
cpe
triplic
cytotox
duplic
six
well
per
plate
set
asid
uninfect
untreat
cell
control
six
well
per
plate
receiv
viru
repres
control
viru
replic
ifn
infergen
tm
titrat
posit
control
drug
set
compound
test
morpholog
chang
result
cytotox
test
compound
viru
cpe
grade
scale
defin
appear
complet
cytotox
cpe
involv
entir
monolay
observ
light
microscopi
valu
obtain
convert
percentag
untreat
uninfect
control
cell
cytotox
concentr
cc
viru
inhibitori
concentr
ic
repres
put
concentr
monolay
would
show
compound
cytotox
viru
cpe
respect
estim
regress
analysi
select
index
si
calcul
use
formula
si
cc
ic
activ
cpe
assay
verifi
spectrophotometr
neutral
red
nr
uptak
assay
plate
neutral
red
nr
uptak
assay
determin
antivir
efficaci
cytotox
test
compound
assay
done
cpe
inhibit
test
plate
describ
verifi
inhibitori
activ
cytotox
detect
visual
observ
experi
usual
correl
visual
neutral
red
nr
uptak
assay
hand
greater
neutral
red
nr
uptak
assay
perform
use
modifi
method
cavanaugh
et
al
describ
barnard
et
al
briefli
medium
remov
well
plate
neutral
red
nr
ad
well
plate
plate
incub
h
c
dark
neutral
red
nr
solut
remov
well
well
rins
remain
dye
extract
use
citrat
buffer
ethanol
absorb
nm
read
micropl
reader
opsi
mr
tm
dynex
technolog
chantilli
va
absorb
valu
express
percentag
untreat
control
ic
cc
si
valu
calcul
describ
viru
yield
reduct
assay
use
confirm
result
cpe
inhibitionnr
uptak
assay
infecti
viru
yield
cpe
inhibit
assay
determin
supernat
test
well
previous
describ
barnard
et
al
cpe
score
describ
plate
frozen
c
thaw
sampl
well
concentr
test
compound
pool
titer
vero
cell
infecti
viru
cpe
assay
previous
describ
barnard
et
al
reduct
viru
yield
ic
calcul
linear
regress
analysi
valu
repres
onelog
inhibit
titer
compar
untreat
viru
control
pseudotyp
virus
gener
cotransfect
cell
g
envencod
plasmid
g
pnlluc
report
backbon
per
dish
presenc
calcium
phosphat
forti
hour
transfect
supernat
filter
screen
purifi
ultracentrifug
rpm
rotor
beckman
coulter
inc
brea
ca
sucros
cushion
store
c
aliquot
zhou
et
al
amount
viru
assess
antigen
captur
enzymelink
immunosorb
assay
elisa
aalto
bio
reagent
ltd
dublin
ireland
cell
seed
white
nunclon
surfac
tissu
cultur
plate
nalgen
nunc
rochest
ny
cellswel
grown
overnight
pretreat
assay
cell
preincub
uda
differ
concentr
c
h
infect
sarscov
pseudotyp
viru
posttreat
assay
cell
infect
sarscov
pseudotyp
viru
h
treat
uda
differ
concentr
addit
sarscov
pseudotyp
viru
preincub
uda
differ
concentr
c
h
addit
cell
plate
incub
day
c
firefli
luciferas
report
express
determin
reagent
promega
madison
wi
percentag
infect
calcul
cell
viabil
assay
cell
seed
treat
uda
quantiti
atp
present
metabol
activ
cell
determin
celltiterglo
luminesc
cell
viabil
assay
system
promega
madison
wi
specif
pathogenfre
femal
g
balbc
mice
obtain
charl
river
laboratori
wilmington
studi
maintain
standard
mous
chow
tap
water
ad
libitum
balbc
mice
quarantin
h
prior
use
anim
studi
carri
approv
biosafeti
level
anim
facil
balbc
mice
anesthet
ml
intraperiton
inject
mgkg
ketamin
sarscov
administ
intranas
volum
ml
group
mice
administ
uda
intraperiton
ip
twice
day
day
bid
begin
h
viru
exposur
poli
ic
lc
administ
intranas
h
viru
exposur
h
exposur
viru
serv
posit
control
control
viru
infect
thirti
mice
treat
ip
pss
h
prior
viru
exposur
h
viru
exposur
twice
day
three
day
mice
group
repres
placebo
control
anim
death
record
day
post
viru
exposur
follow
intranas
administr
sarscov
ld
five
mice
group
sacrif
day
day
sarscovinfect
mockinfect
mice
weigh
everi
day
clinic
sign
diseas
observ
weight
loss
also
determin
infect
uninfect
group
mice
anim
lost
greater
initi
bodi
weight
human
euthan
co
asphyxi
day
euthan
design
day
death
due
infect
uda
dose
rang
find
experi
done
determin
maximum
toler
concentr
three
mice
use
per
treatment
group
toxic
evalu
term
weight
chang
advers
event
advers
event
observ
made
includ
ruffl
fur
lethargi
paralysi
incontin
repetit
circular
motion
aggress
mice
also
weigh
everi
day
h
prior
viru
infect
day
day
post
viru
exposur
lung
scorelung
weight
determin
sampl
mous
lung
lobe
weigh
place
petri
dish
lung
score
base
surfac
appear
lung
lung
assign
score
rang
indic
lung
look
normal
denot
entir
surfac
area
lung
inflam
show
plum
color
lung
discolor
sidwel
et
al
signific
differ
lung
score
determin
kruskalw
test
follow
dunn
pairwis
comparison
post
test
analysi
varianc
anova
use
determin
signific
differ
lung
weight
pairwis
comparison
made
newmankeul
post
test
lung
viru
titer
analyz
mice
sacrif
day
day
post
viru
exposur
lobe
mous
lung
homogen
mem
supplement
fb
tissu
fragment
allow
settl
vari
dilut
supernat
fluid
assay
triplic
infecti
viru
vero
cell
cpe
assay
titer
ccid
valu
calcul
use
reedmuench
method
signific
differ
detect
anova
pairwis
comparison
made
newmankeul
post
test
mice
weigh
group
prior
treatment
everi
day
thereaft
determin
averag
weight
chang
anim
treatment
group
weight
express
group
averag
day
evalu
twoway
analysi
varianc
signific
differ
among
treatment
group
follow
pairwis
comparison
use
bonferroni
post
test
surviv
analysi
done
use
kaplanmei
graphic
method
logrank
test
analysi
reveal
signific
differ
among
treatment
group
therefor
pairwis
comparison
survivor
curv
pss
versu
treatment
analyz
gehanbreslowwilcoxon
pairwis
comparison
test
rel
signific
adjust
bonferronicorrect
signific
threshold
number
treatment
comparison
done
mean
day
death
calcul
analyz
kruskalw
test
follow
dunn
post
test
evalu
signific
pairwis
comparison
live
number
mice
per
total
mice
total
treatment
group
differ
evalu
conting
tabl
analysi
fisher
exact
test
use
make
pairwis
comparison
placebotr
mice
day
day
postinfect
lung
sampl
taken
mice
treatment
group
lung
sampl
time
point
homogen
volum
adjust
lung
weight
immedi
frozen
store
prior
analysi
cytokin
level
supernat
fluid
adjust
total
protein
measur
day
use
quansi
qplex
tm
mous
cytokin
array
quansi
bioscienc
logan
ut
platform
chosen
abil
simultan
measur
differ
mous
cytokin
small
sampl
volum
l
cytokin
contain
alpha
beta
monocyt
chemotact
interferon
gamma
tumor
necrosi
factor
alpha
macrophag
inflammatori
granulocytemacrophag
coloni
stimul
factor
gmcsf
rant
total
protein
sampl
determin
use
bicinchonin
acid
bca
tm
assay
total
protein
valu
use
adjust
measur
cytokin
level
proport
amount
protein
present
sampl
signific
differ
detect
anova
newmankeul
post
test
first
examin
effect
differ
concentr
uda
replic
sarscov
urbani
strain
vero
cell
c
uda
potent
inhibit
viru
replic
tabl
uda
shown
ic
gml
determin
visual
assay
data
shown
ic
gml
determin
neutral
red
nr
uptak
assay
examin
whether
uda
affect
replic
sarscov
strain
uda
inhibit
sarscov
isol
si
valu
rang
determin
neutral
red
uptak
assay
tabl
activ
uda
confirm
viru
yield
reduct
assay
uda
reduc
viru
yield
urbani
strain
gml
vero
cell
correl
well
potent
activ
detect
neutral
red
nr
uptak
assay
uda
also
block
replic
sarscov
strain
reduc
viru
yield
virus
ic
valu
rang
gml
tabl
given
potent
activ
detect
vitro
efficaci
also
evalu
lethal
sarscov
mous
model
mice
randomli
assign
toxic
control
group
gain
weight
rate
nearli
equal
mice
receiv
physiolog
steril
salin
pss
fig
mice
treat
poli
ic
lc
group
mice
lose
notic
amount
weight
occur
day
howev
still
gain
back
lost
weight
nadir
weight
loss
day
mice
group
manag
gain
enough
weight
end
experi
gain
statist
equal
group
mice
advers
event
observ
toxic
control
mice
use
experi
infect
mice
receiv
concentr
uda
poli
ic
lc
protect
seriou
weight
loss
suffer
infect
mice
receiv
placebo
pss
tabl
protect
weight
loss
signific
uda
treatment
group
day
time
least
mice
surviv
treat
ment
group
fig
mice
receiv
uda
poli
ic
lc
went
gain
weight
end
experi
equal
exceed
origin
bodi
weight
record
initi
studi
tabl
experi
mice
receiv
calcul
ld
dose
die
expect
fig
signif
p
versu
pss
p
versu
pss
p
versu
pss
icantli
efficaci
dose
uda
use
treat
infect
mice
uda
mgkgday
dose
mice
significantli
protect
weight
loss
day
tabl
p
thereaft
mice
protect
death
due
viru
infect
p
fig
analysi
death
reveal
dose
uda
significantli
enhanc
ratio
live
mice
total
mice
treatment
group
p
obvious
increas
mean
day
death
p
tabl
interestingli
mgkgday
dose
uda
also
afford
signific
protect
death
evalu
paramet
death
also
protect
weight
loss
fig
tabl
contrast
higher
dose
mgkgday
nearli
protect
death
slightli
toxic
uninfect
mice
day
day
treatment
fig
amelior
weight
loss
infect
treat
mice
critic
day
infect
day
tabl
fig
howev
dose
still
prolong
surviv
mice
evidenc
fact
median
day
death
calcul
day
mice
die
day
addit
even
mice
treat
uda
mgkgday
almost
less
like
die
rapidli
mice
treat
placebo
see
hazard
ratio
tabl
suggest
mgkgday
dose
uda
might
maximum
toler
efficaci
dose
patholog
lung
sarscovinfect
mice
worsen
placebotr
mice
due
combin
viral
damag
alveolar
cell
caus
necrosi
capillari
wall
lead
lung
hemorrhag
well
lateoccur
vascular
phenomena
result
immun
respons
infect
patholog
shown
gross
patholog
lung
also
sever
placebotr
mice
day
evalu
tabl
day
mgkgday
dose
uda
afford
signific
protect
surfac
hemorrhag
inflamm
note
lung
infect
untreat
mice
p
tabl
day
protect
provid
mgkgday
dose
signific
protect
still
significantli
greater
observ
mice
treat
mgkgday
uda
mice
receiv
pss
p
tabl
lung
mice
receiv
mgkgday
dose
uda
display
significantli
littl
surfac
patholog
day
tabl
p
day
tabl
p
dose
effect
dose
uda
amelior
surfac
hemorrhag
inflamm
due
viru
infect
evalu
patholog
effect
edema
treatment
group
measur
indirectli
lung
weight
lung
mice
treat
mgkgday
uda
day
viru
exposur
weigh
slightli
less
lung
mice
group
tabl
day
viru
exposur
group
mice
receiv
uda
poli
ic
lc
much
lower
lung
weight
placebotr
mice
tabl
although
lower
lung
weight
signific
mice
receiv
poli
ic
lc
p
reduct
lung
weight
day
probabl
due
reduct
edema
lung
consolid
signific
mice
receiv
poli
ic
lc
p
pattern
dosag
efficaci
describ
detect
evalu
viru
lung
titer
day
viru
exposur
mice
treat
uda
lower
viru
lung
titer
compar
placebo
treat
mice
except
mice
receiv
uda
mgkgday
tabl
pattern
held
true
day
post
viru
exposur
lung
viru
titer
group
mice
receiv
uda
mgkgday
nearli
equal
record
placebotr
mice
mice
receiv
uda
mgkgday
appear
viru
lung
titer
lower
viru
titer
placebotr
mice
expect
lung
viru
titer
mice
receiv
poli
ic
lc
significantli
reduc
day
day
post
viru
exposur
tabl
p
previou
experi
demonstr
mouseadapt
strain
sarscov
elicit
express
signific
tabl
effect
uda
treatment
variou
measur
lung
paramet
day
post
viru
exposur
balbc
mice
infect
lethal
dose
sarscov
day
lung
score
g
sd
day
lung
weight
g
sd
day
viru
lung
titersg
tissu
sd
pss
amount
cytokin
chemokin
rant
mous
lung
day
infect
measur
multiplex
elisa
assay
day
et
al
current
studi
level
gmcsf
minimum
detect
level
test
group
day
post
viru
exposur
high
level
detect
lung
mice
infect
mouseadapt
strain
fig
level
drop
balbc
mice
treat
uda
mgkgday
poli
ic
lc
mgkgday
fig
although
recogniz
decreas
cytokin
decreas
statist
signific
contrast
day
lung
infect
mice
treat
uda
mgkgday
poli
ic
lc
mgkgday
much
higher
rant
level
compar
day
valu
lung
infect
untreat
mice
fig
investig
uda
might
inhibit
sarscov
infect
studi
mode
action
vitro
uda
ad
cell
pretreat
addit
viru
cell
adsorpt
viru
posttreat
cell
uda
pretreat
vero
cell
treat
uda
h
infect
viru
uda
posttreat
vero
cell
infect
sarscov
h
treat
uda
mark
inhibitori
effect
sarscov
replic
observ
treatment
occur
viru
exposur
cell
inhibit
three
time
less
treatment
occur
adsorpt
tabl
effect
even
pronounc
compar
ic
valu
viru
yield
reduct
assay
pretreat
cell
uda
result
ic
gml
also
test
whether
uda
would
affect
sarscov
replic
h
infect
treatment
uda
h
infect
inhibit
sarscov
replic
order
examin
possibl
inhibitori
effect
due
direct
bind
uda
sarscov
uda
ad
viru
h
inocul
mark
inhibit
sarscov
replic
observ
compar
uda
pretreat
cell
suggest
uda
might
react
directli
sarscov
tabl
investig
whether
uda
play
role
earli
step
viral
infect
next
examin
effect
uda
sarscov
pseudotyp
viru
infect
target
cell
confirm
describ
pretreat
uda
posttreat
cell
result
signific
dosedepend
reduct
infect
fig
addit
preincub
sarscov
pseudotyp
viru
uda
c
h
cell
also
result
signific
dosedepend
reduct
infect
fig
uda
inhibit
almost
potent
compar
treat
uda
h
viru
adsorpt
thu
inhibit
live
sarscov
sarscov
pseudotyp
viru
infect
indic
uda
act
earli
step
viral
infect
better
determin
target
step
uda
sarscov
life
cycl
timeofaddit
assay
perform
accord
method
previous
describ
keyaert
et
al
vero
cell
infect
mouseadapt
sarscov
multipl
infect
ensur
almost
cell
expos
viru
order
studi
singl
cycl
viru
replic
h
adsorpt
cell
wash
medium
uda
gml
almost
time
ic
ad
variou
time
point
infect
simultan
uda
found
inhibit
earli
phase
h
infect
late
phase
h
infect
sarscov
life
cycl
previous
shown
tabl
sinc
uda
bind
nacetylglucosamin
examin
whether
uda
would
affect
bind
site
cellsurfac
sugar
chain
vero
cell
vero
cell
incub
uda
h
uda
remov
cell
wash
medium
aspir
near
dryness
infect
sarscov
urbani
strain
incub
continu
day
antivir
activ
determin
describ
experi
treatment
cell
uda
infect
inhibit
sarscov
replic
vero
cell
suggest
uda
affect
bind
site
cellsurfac
sugar
chain
vero
cell
data
shown
similar
result
obtain
cell
treat
uda
h
wash
medium
infect
sarscov
pseudotyp
viru
data
shown
experi
concentr
cellfre
sarscov
urbani
isol
expos
uda
variou
concentr
h
c
udaexpos
viru
suspens
titrat
vero
cell
plate
endpoint
dilut
describ
previous
barnard
et
al
assay
done
triplic
day
day
post
infect
viral
titer
vero
cell
quantifi
describ
preexposur
sarscov
uda
shown
block
viral
replic
dosedepend
manner
fig
titrat
uda
dilut
well
ec
concentr
see
tabl
indic
antivir
effect
result
incub
uda
viru
carryov
compound
titrat
data
indic
uda
neutral
viru
infect
presum
bind
sarscov
spike
glycoprotein
sarscov
expos
uda
h
udaexpos
viru
suspens
titrat
vero
cell
b
effect
live
sarscov
infect
nacetylglucosamin
viru
titer
per
ml
nacetylglucosamin
expos
uda
c
h
nacetylglucosamineexpos
uda
incub
concentr
cellfre
sarscov
urbani
isol
c
anoth
h
determin
activ
uda
sarscov
due
specif
interact
spike
glycoprotein
addit
experi
util
nacetylglucosamin
evalu
antivir
activ
vitro
nacetylglucosamin
incub
uda
c
h
nacetylglucosamineexpos
uda
incub
concentr
cellfre
sarscov
urbani
isol
c
h
viru
titrat
vero
cell
studi
show
nacetylglucosamineexpos
uda
prevent
sarscov
infect
wherea
uda
treat
nacetylglucosamin
reduc
viral
titer
fig
data
indic
uda
neutral
viru
infect
bind
moieti
nacetylglucosamin
presum
found
viru
protein
respons
adsorpt
demonstr
potent
inhibit
sarscov
replic
cell
cultur
neutral
red
uptak
assay
viru
yield
reduct
assay
also
shown
uda
inhibit
retrovir
particl
pseudotyp
sarscov
spike
infect
vitro
suggest
function
sarscov
spike
protein
might
target
uda
vitro
inhibitori
activ
also
translat
inhibit
virusinduc
mortal
lethal
sarscov
challeng
model
mice
reduc
viru
lung
titer
one
possibl
explain
efficaci
uda
spite
significantli
reduc
viru
titer
may
attribut
put
mechan
action
support
data
previous
describ
like
uda
inhibit
attach
thu
limit
spread
viru
infect
cell
uninfect
cell
bind
releas
viru
prevent
attach
uninfect
cell
sinc
current
studi
entir
lung
harvest
homogen
titrat
viru
would
way
differenti
intracellular
infecti
viru
viru
releas
infect
cell
bronchial
fluid
lung
lavag
assay
viru
may
well
decreas
titer
releas
extracellular
viru
respons
uda
treatment
especi
day
day
maxim
viru
titer
lung
homogen
achiev
day
post
challeng
multipl
cytokin
chemokin
rant
significantli
elev
lung
balbc
mice
infect
mouseadapt
sarscov
similar
find
also
report
chen
subbarao
yen
et
al
show
human
monocyt
cell
line
suscept
sarscov
studi
sarscov
induc
cell
express
rant
li
et
al
report
rant
inhibit
sarscov
replic
cell
ad
cultur
time
sarscov
infect
report
significantli
high
level
mous
rant
lung
balbc
mice
detect
sarscovinfect
mice
treat
uda
poli
ic
lc
indic
elev
rant
inhibit
diseas
progress
addit
strongli
express
sarscovinfect
mice
also
observ
human
sar
patient
chen
subbarao
jiang
et
al
demonstr
superinfect
immun
injuri
acut
respiratori
distress
well
lung
failur
main
caus
death
rapid
increas
sign
superinfect
indic
high
risk
death
convers
observ
detect
level
drop
balbc
mice
treat
uda
poli
ic
lc
therefor
cytokinechemokin
like
good
earli
indic
diseas
outcom
mice
angiotensinconvert
enzym
identifi
function
receptor
sarscov
also
call
lsign
dcsignr
differ
human
cellular
glycoprotein
demonstr
altern
receptor
sarscov
jeffer
et
al
plant
lectin
sugarbind
protein
high
affin
specif
sugar
residu
play
import
role
biolog
recognit
phenomena
involv
cell
protein
virus
use
lectin
attach
host
cell
initi
infect
jeffer
et
al
sarscov
antigen
detect
alveolar
epitheli
cell
primarili
type
ii
pneumocyt
bronchial
epitheli
cell
alveolar
macrophag
respiratori
tract
ding
et
al
ye
et
al
cell
type
express
human
lung
type
ii
alveolar
cell
mediat
infect
sarscov
jeffer
et
al
sarscov
spike
glycoprotein
attach
use
earli
step
viral
infect
previou
studi
shown
sarscov
spike
glycoprotein
bind
cell
surfac
lectin
dcsign
dcsignr
marzi
et
al
yang
et
al
need
determin
whether
uda
block
bind
sarscov
dcsign
dcsignr
vitro
data
suggest
mode
inhibit
lectin
uda
might
bind
virion
prevent
adsorpt
perhap
uda
bind
epitop
found
sarscov
spike
protein
bind
dcsign
dcsignr
mani
envelop
virus
glycoprotein
surfac
glycoprotein
mediat
receptor
bind
membran
fusion
virion
host
cell
therefor
attract
therapeut
target
novel
antivir
therapi
van
der
meer
et
al
use
immunoperoxidas
stain
assay
luciferasebas
assay
evalu
antivir
activ
uda
show
uda
inhibit
nidoviral
vitro
assay
base
number
infect
cell
express
viral
protein
uda
bind
viral
glycoprotein
inhibit
viru
entri
target
cell
balzarini
keef
et
al
recent
report
potent
antivir
lectin
griffithsin
grst
kda
protein
origin
isol
red
alga
griffithsia
sp
inhibit
sarscov
infect
vitro
vivo
grst
known
bind
nacetylglucosamin
also
mannos
multival
manner
via
three
independ
carbohydratebind
domain
ziolkowska
et
al
grst
specif
bound
sarscov
spike
glycoprotein
inhibit
viral
entri
like
sarscov
spike
protein
heavili
glycosyl
contain
put
nglycosyl
site
krokhin
et
al
rota
et
al
also
confirm
inhibitori
effect
sarscov
infect
observ
uda
ad
live
sarscov
urbani
strain
sarscov
pseudotyp
viru
h
inocul
suggest
uda
might
react
directli
sarscov
base
observ
examin
whether
uda
would
affect
bind
site
cellsurfac
sugar
chain
vero
cell
uda
remov
h
treatment
cell
wash
medium
infect
reduct
viral
cpe
observ
data
suggest
uda
affect
bind
site
cellsurfac
sugar
chain
furthermor
demonstr
uda
neutral
viru
infect
presum
bind
sarscov
spike
glycoprotein
support
ritchi
et
al
identifi
nglycan
associ
sarscov
spike
protein
demonstr
major
total
glycan
nglycan
highmannos
hybrid
bi
tri
tetraantennari
complex
glycan
mani
termin
residu
antennari
coupl
appear
nacetylglucosamin
glycan
uda
preferenti
bind
howev
author
map
posit
residu
within
protein
determin
whether
cluster
nglycan
complex
attach
portion
protein
fusion
portion
protein
nevertheless
data
support
conclus
uda
like
bind
protein
via
nacetylglucosamin
residu
sarscov
protein
inhibit
attach
cell
therebi
prevent
viru
infect
cell
although
vitro
data
suggest
one
mode
inhibit
might
bind
uda
virion
prevent
adsorpt
anoth
possibl
need
investig
whether
uda
might
protect
mice
viru
challeng
regul
immun
respons
addit
lieu
inhibit
sarscov
directli
exampl
found
uda
might
function
superantigen
lectin
activ
tcell
respons
cytokin
product
galelli
truffabachi
mechan
immun
modul
also
support
signific
increas
rant
level
infect
mice
receiv
uda
treatment
compar
rant
level
detect
untreat
infect
mice
given
demonstr
vitro
vivo
inhibit
sarscov
replic
uda
analog
might
qualifi
potenti
therapi
treat
sarscov
infect
